Cigna clarifies coverage for cladribine (Mavenclad® and generics) for adults with relapsing forms of MS, aligning use with FDA safety limits and recommending it mainly for patients who failed or cannot tolerate alternative DMTs. Initial and continuing approvals are time‑limited to 1 year and require prescriber documentation of prior therapy failure or high‑activity disease for initiation, and objective evidence of benefit or stabilization for continuation. Treatment must be prescribed by or in consultation with a neurologist or MS specialist. Use is not covered for clinically isolated syndrome, non‑relapsing MS phenotypes (e.g., primary progressive MS), or in combination with other MS DMTs.
March 2026 Revision: Cladribine Indication and Approval Duration Clarified
This Cigna policy (IP0261) for cladribine (Mavenclad® and generic cladribine tablets) establishes the approved indications, duration of approval, and explicit limitations reflective of the FDA labeling and the drug's safety profile. The document’s effective date is 2026-03-01 and it focuses on treatment of relapsing forms of multiple sclerosis (MS) in adults. A central framing in this revision is the emphasis that cladribine is generally recommended only for patients who have had an inadequate response to, or cannot tolerate, alternate MS disease‑modifying therapies, consistent with the FDA limitation of use due to safety concerns.
The revision also clarifies conditions under which initial and continuing therapy will be approved. Initial therapy approval is specified for 1 year when detailed clinical criteria are met (relapsing form of MS plus prescriber-documented prior therapy failures or other high‑activity disease criteria and neurologist involvement). Continuing (current) cladribine therapy is likewise approved for 1 year if documented clinical benefit or stabilization is shown and the prescriber is a neurologist or MS specialist.
Specific Approval Criteria for Initial and Continuing Use of Cladribine
The policy limits FDA‑approved use of cladribine to adults with relapsing forms of MS — examples explicitly called out include relapsing remitting MS and active secondary progressive MS. For initial therapy, the policy requires the patient to have a relapsing form of MS and to satisfy one of the enumerated prior‑therapy or disease‑activity criteria. These include either inadequate efficacy or intolerability to two MS disease‑modifying agents, or to one of the highest‑efficacy agents listed (e.g., Kesimpta, natalizumab products, Briumvi, Lemtrada, Ocrevus products), prior use of cladribine, or prescriber assessment of highly active/aggressive MS as defined by clinical deterioration, disabling relapses with suboptimal steroid response, MRI evidence of high activity, or MS‑related cognitive impairment.
Approvals for both initial and continuing therapy are time‑limited to 1 year under the policy and require that the medication be prescribed by or in consultation with a neurologist or physician who specializes in MS treatment. For continuing therapy, the policy specifies that continued approval requires objective evidence of benefit (examples include MRI stabilization/reduction of lesions, EDSS stabilization, attainment of NEDA criteria, reduced relapses, or functional/symptom improvements) or stabilization/improvement in at least one MS symptom domain.
Explicit Non‑Covered Indications and Combination Therapy Exclusions
The policy enumerates explicit uses that are considered not medically necessary. Cladribine is not recommended for clinically isolated syndrome because of safety concerns per the FDA limitation of use. The policy also excludes use in non‑relapsing forms of MS — it notes that efficacy has not been established for such phenotypes and explicitly cites primary progressive MS as an example of a non‑relapsing form.
Additionally, coadministration with other MS disease‑modifying agents is designated as not covered. The policy states that these agents are not indicated for combination use, and that additional data are required to determine the safety and efficacy of combination regimens. The document references an Appendix for examples of agents that should not be combined with cladribine.
Definitions and Examples for High‑Activity MS and Objective Benefit Measures
The policy frames clinical definitions and examples to guide interpretation of the criteria. For example, the document lists manifestations that can constitute highly‑active or aggressive multiple sclerosis: rapidly advancing deterioration in physical functioning (with examples such as loss of mobility or severe changes in strength/coordination), disabling relapses with suboptimal steroid response, MRI findings such as new/enlarging or high burden T2 or gadolinium‑enhancing lesions, and MS‑related cognitive impairment. These examples are presented as ways prescribers may document eligibility under the high‑activity criterion.
For measurement of continuing benefit, the policy provides multiple objective endpoints that may support renewal: MRI lesion activity, EDSS, NEDA‑3 or NEDA‑4 status, fatigue scales, relapse reduction, walking/function tests (six‑minute walk, 12‑Item MS Walking Scale), MSFC score, and attenuation of brain volume loss. These examples illustrate the policy’s emphasis on objective measures of disease activity or stabilization when authorizing ongoing cladribine therapy.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.